Skip to main content
WAT logo

WAT · Waters Corp

Track WAT — free
$453.42 -6.83 (-1.48%) At close · Nov 16
Market Cap
$44.56B
Shares
98.29M
Volume · Nov 16 575.68K Avg daily vol (3M) 826.37K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$453.42 Open$455.12 Day$451.57–460.05 52W close$283.32–480.07 Avg vol 30d966K Short int3.3M · 3.4% of shares · 3.6d Short vol53% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 10

Up next

Feb 8, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Oct 3
Revenue rises sharply as operating income falls

For the three months ended October 3, 2026, Waters reported total net revenues of 1,767 million, up from 800 million. Operating income fell to 128 million from 192 million, and net income declined to 81 million from 149 million.

Revenue $1.77B ▲ 120.9% Net income $81M ▼ 45.6% Diluted EPS $0.82 ▼ 67.2%
Read from the first part of this long document
5 source passages
Waters Corporation (the “Company,” “Waters,” “we,” “our,” or “us”), is a global life sciences leader in the development, manufacturing, and sale of analytical instruments, reagent systems and software. For the quarterly period ended October 3, 2026 Total net revenues | | 1,767 | 800 Operating income | | 128 | 192 Net income | | 81 | 149 Open the document at this passage
Nov 3
Current report 8-K
Revenue $1.767 billion; 2026 guidance raised

Waters Corporation reported third quarter of 2026 revenue of $1.767 billion and adjusted EPS of $4.10, up 21%, while raising full-year 2026 guidance.

Financial results
4 source passages
MILFORD, Mass., November 3, 2026 - Waters Corporation (NYSE: WAT) today announced its financial results for the third quarter of 2026. The Company’s reported revenue for the third quarter of 2026 was $1.767 billion, reflecting $871 million of organic revenue and $896 million of revenue from the acquired Biosciences and Diagnostic Solutions businesses. Adjusted EPS for the third quarter of 2026 grew 21% to $4.10, compared to $3.40 for the third quarter of 2025. The Company is raising every component of its full-year 2026 guidance, including a $43 million increase to total reported revenue at the midpoint, as new growth vectors layer onto a strong foundation of existing demand. Open the document at this passage
Sep 23
Investor event
J.P. Morgan U.S. All Stars Conference

Waters Corp reported 2Q organic growth of 9% and reached a 200 million cost-synergy run rate within nine months, versus its original three-year target. Management expects the acquired businesses to accelerate and significant margin expansion in 2027.

Aug 11
Quarterly report 10-Q FY2026 Q2, ended Jul 4
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.65B ▲ 113.4% Net loss $136M Diluted EPS -$1.39
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.61B
Trailing 12 months
Net income (TTM)
$98.63M
Trailing 12 months
Revenue growth YoY
+120.9%
Year over year
Operating margin
4.7%
Trailing 12 months
P / E (TTM)
197.5
Trailing earnings · reciprocal yield 0.5%
FCF yield
0.6%
TTM · current market cap
Return on invested capital
1.2%
Trailing 12 months
Net cash
−$4.54B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+66.0%
Year over year · more shares
Price change (1Y)
+21.3%
Trailing year
Short interest
3.4%
Latest settlement · 3.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bearish Fundamentals Fair Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +21%
above
Price vs 50-day avg +3%
above
RSI (14) 49
neutral
MACD trend Negative
52-week position 86%
near high
Momentum
relative strength
Very Strong
1-month return +4%
trailing
6-month return +33%
trailing
YTD return +19%
this year
Relative strength +34%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $441 › 200d $374 — 50d above 200d
Institutional flow Distributing
-5% holders QoQ · +126 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.39% of shares out · ▲ +4.3% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,134 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Fair
Revenue growth +7%
Y/Y
Gross margin 38%
contracting
EPS growth +0%
Y/Y
Buyback $1.0B
remaining
Balance sheet $819.0M
net debt
Quant / Vol
risk profile
Moderate
Volatility 35%
annualized · 1-yr
Max drawdown −31%
past year
ATR 3.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 7
Latest guidance · from the 8-K filed Aug 4, 2026
Organic constant currency revenue growth · full-year 2026 Raised 7% – 9%
May 5, 2026 6.5% – 8% changed to Aug 4, 2026 7% – 9%
Organic reported revenue · full-year 2026 Raised $3.37B – $3.43B
May 5, 2026 $3.37B – $3.42B changed to Aug 4, 2026 $3.37B – $3.43B
Acquired business reported revenue · full-year 2026 Raised $3.05B
May 5, 2026 $3.04B changed to Aug 4, 2026 $3.05B
Total Company reported revenue · full-year 2026 Raised $6.42B – $6.48B
May 5, 2026 $6.41B – $6.46B changed to Aug 4, 2026 $6.42B – $6.48B
prior FY $3.17B midpoint +103.6% Y/Y
Adjusted EPS · full-year 2026 Raised $14.45 – $14.65
May 5, 2026 $14.40 – $14.60 changed to Aug 4, 2026 $14.45 – $14.65
Previous outlook earlier release · from the Earnings Call filed May 5, 2026

Still-open targets the latest release did not restate under the same label.

Organic constant currency revenue growth · full year 2026 6.5% – 8%
Adjusted EBIT margin · full year 2026 28.2%
Incremental revenue · over the next five years at least $20M
Chemistry growth · full year 6.5%
Prior guidance period ended · from the 8-K filed Aug 4, 2026
Organic constant currency revenue growth · third quarter 2026 8% – 10%
Organic reported revenue · third quarter 2026 $850M – $867M
Acquired business reported revenue · third quarter 2026 $895M
Total Company reported revenue · third quarter 2026 $1.75B – $1.76B
Adjusted EPS · third quarter 2026 $3.95 – $4.05
Guided vs delivered · last 7 settled
Total Company reported revenue third quarter 2026
guided $1.75B – $1.76B
$1.77B Beat +0.8%
Reported revenue second quarter 2026
guided $1.62B – $1.63B
$1.65B Beat +1.3%
Total Company revenue first quarter 2026
guided $1.2B – $1.21B
$1.27B Beat +5.2%
GAAP earnings per diluted share Twelve Months Ended December 31, 2024
guided $10.90 – $11.20
$10.71 Miss −3.1%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+21% Bullish
Price vs 50-day avg
+3% Bullish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
86% Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $441 › 200d $374 — 50d above 200d
Institutional flow Distributing
-5% holders QoQ · +126 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.39% of shares out · ▲ +4.3% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,134 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $283 Now $453 · 86% Range high $480
vs 200-day avg +21% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Acquired Business Contribution non-GAAP 1.34B Six Months Ended July 4, 2026 —
ASD Instrument Revenue 240M Three Months Ended July 4, 2026 —
Constant Currency ASD Instrument Revenue Growth non-GAAP 8% Three Months Ended July 4, 2026 —
Free Cash Flow - Adjusted Non-GAAP non-GAAP $161M Six Months Ended July 4, 2026 —
GAAP → non-GAAP reconciliation
GAAP Net cash provided by operating activities - GAAP 200M
-49M Additions to property, plant, equipment, and software capitalization
+0M Tax reform payments
+0M Litigation settlements received, net
+0M Payment of Wyatt retention bonus obligation
+51M Change in deposit asset
= Free Cash Flow - Adjusted Non-GAAP 202M
Organic Constant Currency Revenue Growth non-GAAP 10% Six Months Ended July 4, 2026 —
Organic Reported Revenue Growth non-GAAP 10% Six Months Ended July 4, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
WAT
Waters Corp
this stock
$44.56B +19.4% +7.0% — 3.4%
TMO
Thermo Fisher Scientific Inc.
$256.15B +19.3% +14.5% 36.5 1.3%
DHR
Danaher Corp
$161.75B +0.4% +8.5% 37.6 1.2%
IDXX
Idexx Laboratories Inc
$55.20B +3.6% +10.4% 47.2 3.0%
A
Agilent Technologies, Inc.
$48.75B +27.1% +6.4% 34.0 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,134
% held
90.8%
Net QoQ
-8.6M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
915
View
Short & Settlement
Short Interest Rising
Shares short
3.3M
Days to cover
3.6d
Change
+138.2K sh
View
Short Volume
Short vol %
53%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
77
Value
$35.1K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
52.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Kevin Hern
Amount
$1.0K–$15.0K
Traded
Aug 13, 2026
View
Financials
Financials
Revenue (FY)
$3.2B
Net income (FY)
$642.6M
EPS diluted
$10.76
View
Buybacks
Authorized
$4.8B
Remaining
$1.0B
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 10, 2026
This year
21

For the three months ended October 3, 2026, Waters reported total net revenues of 1,767 million, up from 800 million. Operating income fell to 128 million from 192 million, and net income declined to 81 million from 149 million.

View
Proposed Sales
Value
$1.4M
Shares
3.6K
Filed
Aug 6, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
Waters Achieves FDA 510(k) Cleara…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
WAT -4.9% +4.4% +32.5% -2.0% +19.4%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -3.2% +7.9% +33.9% +0.1% +10.9%

Capital returns

Buyback program · as of Jul 4, 2026
Authorized
$4.80B
Spent (derived)
$3.80B
Remaining
$1.00B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1000697 CUSIP 941848103 13F (30d) 1033 filings 986 filers Visit website Investor relations